Bioproduction in the US pharmaceutical industry is crucial for delivering life-saving medications efficiently. Advancements in biotechnology and rising demand are driving rapid evolution in bioproduction. While state-of-the-art facilities and strict regulations define the sector, challenges in scalability, cost-effectiveness, and compliance persist, necessitating ongoing innovation and collaboration across academia, government, and industry for a sustainable ecosystem. 

Reviewing emerging technologies such as continuous bioprocessing and single-use systems and their role in transforming bio-production in the US?  

How can regulatory frameworks evolve to support biopharmaceutical innovation while maintaining patient safety and product quality under the FDA's emphasis on advancing regulatory science?